Ken Griffin Alx Oncology Holdings Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.81 - $8.13 $66,608 - $299,184	36,800 Added 105.75%	71,600 $130,000
Q2 2024 Aug 14, 2024	BUY	$5.84 - $17.56 $150,088 - $451,291	25,700 Added 282.42%	34,800 $209,000
Q1 2024 May 15, 2024	SELL	$10.95 - $16.79 $187,245 - $287,109	-17,100 Reduced 65.27%	9,100 $101,000
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $59,643 - $190,712	12,400 Added 89.86%	26,200 $390,000
Q3 2023 Nov 14, 2023	SELL	$4.19 - $7.35 $25,978 - $45,570	-6,200 Reduced 31.0%	13,800 $66,000
Q2 2023 Aug 14, 2023	BUY	$4.37 - $9.56 $71,668 - $156,784	16,400 Added 455.56%	20,000 $150,000
Q1 2023 May 15, 2023	SELL	$4.52 - $11.71 $7,231 - $18,736	-1,600 Reduced 30.77%	3,600 $16,000
Q4 2022 Feb 14, 2023	SELL	$9.51 - $12.95 $351,870 - $479,150	-37,000 Reduced 87.68%	5,200 $58,000
Q3 2022 Nov 14, 2022	SELL	$8.23 - $15.14 $385,164 - $708,552	-46,800 Reduced 52.58%	42,200 $404,000

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $61.5M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.